Imagene, a Miami-based precision oncology diagnostics company, is advancing AI-powered technologies to enhance cancer treatment decision-making. Leveraging an Oncology Intelligence foundation model trained on over 1.5 million biopsy images across 40 tissue types, Imagene integrates genomic, proteomic, and spatial biomarker data to predict cancer patient outcomes and stratify patients for clinical trials. Supported by notable investors including Oracle founder Larry Ellison, the platform provides tools for identifying prognostic biomarkers and designing clinical trials, aiming to personalize therapeutic approaches and improve clinical success rates in oncology.